PsychoGenics

Established over 20 years ago, PsychoGenics is a preclinical contract research organization (CRO) with expertise in central nervous system (CNS) and orphan disorders. They’ve developed multiple AI-enabled proprietary technologies to analyze mice behavior, and recently added a pipeline of their own drug candidates originated from their technologies.

Referred to us by Jefferies investment bankers, PsychoGenics is known in the industry as a CRO and needed help restructuring their corporate story to include their drug development capabilities without distracting from their CRO services.

The PsychoGenics project consisted of creating a presentation deck and various digital marketing materials, including making changes to their existing website. We began by familiarizing ourselves with their history, capabilities, and technology through reviews of materials and interviews with the PsychoGenics leadership team. This information helped us devise a strategy for presenting their extensive CRO offerings and new drug development path in a way that unifies these potentially divergent missions around the unique and novel technologies PsychoGenics developed.

The Psychogenics logo and tagline 'redefining drug discovery through innovation' are displayed above a stylized illustration of a human brain with circuit-like pathways. This visually represents their focus on central nervous system disorders and innovative drug discovery.
This slide showcases Psychogenics' four proprietary in vivo technologies – SmartCube®, NeuroCube®, PhenoCube®, and eCube™ – which form the core of their drug discovery platform. Each technology assesses different aspects of animal behavior and brain activity with high throughput.
This illustration emphasizes the complex nature of neuropsychiatric disorders, showing how multiple susceptibility genes, epigenetic factors, and environmental factors interact, requiring a novel drug discovery approach, which Psychogenics aims to provide.
This slide contrasts traditional phenotypic drug discovery with Psychogenics' approach. It points out limitations of traditional methods such as subjectivity, prolonged timelines, and high costs, even though it has led to effective treatments.
This slide highlights the significant unmet needs in various central nervous system disorders, including Schizophrenia, Generalized anxiety disorder, Depression, and Bipolar disorder. It presents worldwide prevalence, first-line relapse rates, and key limitations of current treatment options.
This diagram outlines Psychogenics' faster and more efficient process for discovering and validating novel compounds. It includes steps from a novel compound being tested in animal models, data integration into their platform (database, hardware, AI), behavioral signature analysis, prediction of therapeutic indications, and compound validation.